SCIREQ - an emka TECHNOLOGIES Company news
Recent advances in the fight against severe acute inflammatory lung diseases, including COVID-19, have revealed a promising new approach to treating pulmonary hyperinflammation and long-term lung damage such as fibrosis. A groundbreaking study has developed a first-in-class, carbohydrate-coupled inhibitor of microRNA-21 (RCS-21), which shows significant potential as a therapeutic agent. This inno
Idiopathic pulmonary fibrosis (IPF) remains a devastating condition with limited treatment options, often leading to a grim prognosis. However, a recent study by Milman-Krentsis (2024) offers a beacon of hope, demonstrating the potential of lung cell transplantation as a therapeutic intervention for lung fibrosis. Utilizing two distinct mouse models—one treated with bleomycin and another genetically modified to la
The incidence of landscape fires has been rising globally, leading to increased exposure to landscape fire smoke (LFS) among millions of people. The inhalation of particulate matter (PM) from LFS is associated with adverse respiratory and cardiovascular outcomes. However, the mechanisms by which LFS impacts these functions remain i
Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) are major global health threats. Their interaction worsens disease severity, as HIV reduces CD4+ T cells, making individuals more vulnerable to TB. Despite progress, an effective animal model that mimics human immune response during HIV/TB co-infection has been lacking, hindering treatment and vaccine development.
The rise of antibiotic-resistant bacteria has driven renewed interest in alternative treatments, including phage therapy. A recent study by Yang, F., et al (2024) explores the potential of bacteriophage therapy for treating multi-drug resis